Pirfenidone, an antifibrotic agent that blocks profibrogenic mediators such as TGF-β and TNF-α [14], was evaluated in the ASCEND clinical trial where it demonstrated decreased IPF progression (over placebo), with tolerable side effects [15]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.